This grant is for supporting investigator-initiated large-scale clinical trials, human gene-transfer, or stem cell therapy trials focused on vision disorders. The National Eye Institute (NEI) uses these UG1 cooperative agreement awards for multifaceted projects of high public health significance, requiring careful oversight and patient safety monitoring. Proposed studies must evaluate interventions for screening, diagnosing, preventing, or treating vision disorders, or compare existing treatments. This specific funding opportunity encourages applications for a Resource Center grant. Resource Centers provide crucial imaging, laboratory, or other services essential for supporting multi-center clinical trials or other complex and high-risk clinical investigations in ophthalmology, ensuring the success and integrity of critical vision research.
Opportunity ID: 329873
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-21-043 |
| Funding Opportunity Title: | NEI Collaborative Clinical Vision Project: Resource Center Grant (UG1- Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.867 — Vision Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Nov 18, 2020 |
| Last Updated Date: | Nov 18, 2020 |
| Original Closing Date for Applications: | May 07, 2023 |
| Current Closing Date for Applications: | May 07, 2023 |
| Archive Date: | Jun 12, 2023 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | State governments Public and State controlled institutions of higher education For profit organizations other than small businesses Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments Native American tribal governments (Federally recognized) County governments Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Independent school districts Private institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The NEI uses UG1 cooperative agreement awards to support investigator-initiated large-scale clinical trials, human gene-transfer and stem cell therapy trials, and other complex or high resource- or safety-risk clinical trials. These projects are multifaceted and of high public health significance, requiring clear delineation of study organization including roles and responsibilities and require careful performance oversight and monitoring for patient safety. For purposes of this Funding Opportunity Announcement (FOA), the proposed study must be intended to evaluate interventions aimed at screening, diagnosing, preventing, or treating vision disorders, or to compare the effectiveness of two or more established interventions. The NEI UG1-supported studies are typically funded as a group of linked companion grant awards including the Chairs Grant, the Coordinating Center, and Resource Centers, when appropriate. For less organizationally complex projects, details pertaining to data management and statistical analyses, resource center and recruitment activity may be included as part of the Chair’s Grant application. Specifically, this FOA encourages applications for the Resource Center grant which provides imaging, laboratory, or other requisite services for a multi-center clinical trial or other complex or high risk clinical trial. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-21-043.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 329873 Full Announcement-PAR-21-043 -> PAR-21-043-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00264157 | Dec 25, 2020 | Jan 24, 2022 | View | |
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00269582 | Oct 27, 2021 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00277593 | Oct 31, 2022 | May 07, 2023 | View |
Package 1
Mandatory forms
329873 RR_SF424_2_0-2.0.pdf
329873 PHS398_CoverPageSupplement_5_0-5.0.pdf
329873 RR_OtherProjectInfo_1_4-1.4.pdf
329873 PerformanceSite_2_0-2.0.pdf
329873 RR_KeyPersonExpanded_2_0-2.0.pdf
329873 RR_Budget_1_4-1.4.pdf
329873 PHS398_ResearchPlan_4_0-4.0.pdf
329873 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
329873 RR_SubawardBudget30_1_4-1.4.pdf
329873 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
329873 RR_SF424_5_0-5.0.pdf
329873 PHS398_CoverPageSupplement_5_0-5.0.pdf
329873 RR_OtherProjectInfo_1_4-1.4.pdf
329873 PerformanceSite_4_0-4.0.pdf
329873 RR_KeyPersonExpanded_4_0-4.0.pdf
329873 RR_Budget_3_0-3.0.pdf
329873 PHS398_ResearchPlan_4_0-4.0.pdf
329873 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
329873 RR_SubawardBudget30_3_0-3.0.pdf
329873 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 3
Mandatory forms
329873 RR_SF424_5_0-5.0.pdf
329873 PHS398_CoverPageSupplement_5_0-5.0.pdf
329873 RR_OtherProjectInfo_1_4-1.4.pdf
329873 PerformanceSite_4_0-4.0.pdf
329873 RR_KeyPersonExpanded_4_0-4.0.pdf
329873 RR_Budget_3_0-3.0.pdf
329873 PHS398_ResearchPlan_5_0-5.0.pdf
329873 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
329873 RR_SubawardBudget30_3_0-3.0.pdf
329873 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
